|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association between telomerase reverse transcriptase (TERT) promoter mutations and some clinical behaviors in thyroid cancer remains controversial and requires additional investigation.
|
31655978 |
2020 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).
|
31669704 |
2020 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to search for novel TERT promoter mutations and additional mechanisms of TERT activation in thyroid cancer.
|
31408918 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations were likely to occur in BRAF V600E positive TC.
|
30024548 |
2018 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Telomerase reverse transcriptase (TERT) promoter mutations have recently been identified as an important prognostic factor in thyroid cancer.
|
30102829 |
2018 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study also confirmed the occurrence of TERT promoter mutations in high-risk thyroid cancers.
|
29723601 |
2018 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We confirmed the absence of TERT promoter mutations in benign follicular neoplasms and found a low frequency of TERT promoter mutations in our selected cohort of low-risk follicular-patterned malignancies, speculating their role in the progression and de-differentiation of thyroid cancer.
|
28975450 |
2017 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The presence of a telomerase reverse transcriptase (TERT) promoter mutation has been suggested as a potential prognostic marker for thyroid cancer, and a synergistic association with the BRAF<sup>V600E</sup> mutation has been demonstrated.
|
28181854 |
2017 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of TERT promoter mutations in preoperative fine-needle aspiration biopsy specimens may help in better characterizing the prognosis and triaging thyroid cancer patients for appropriate treatment.
|
27184112 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations and long-term survival in patients with thyroid cancer.
|
27528624 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Future studies will specifically define such clinical utilities, elucidate the biological mechanisms and explore the potential as therapeutic targets of TERT promoter mutations in thyroid cancer.
|
26733501 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed Sanger sequencing to detect BRAF V600E and TERT promoter mutations and both immunohistochemistry and fluorescence in situ hybridization to identify ALK rearrangement on 243 thyroid cancers.
|
26857243 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Only one case of pediatric TC was found to harbor the C228T TERT promoter mutation (1.8%).
|
26711586 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT Promoter Mutations in Thyroid Cancer.
|
26902827 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A telomerase reverse transcriptase (TERT) promoter mutation was identified in thyroid cancer.
|
26727717 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the TERT promoter were recently reported to correlate strongly with aggressiveness in advanced forms of thyroid cancer, holding promise for a possible clinical application.
|
26148423 |
2015 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of 265 TC, 34 (12.8%) harbored TERT promoter mutations, including 10/153 (6.5%) conventional papillary TC (CPTC), 8/57 (14.0%) follicular variant PTC, 9/30 (30%) tall cell variant PTC, 1/3 (30%) Hurthle cell thyroid cancer (HTC), 1/5 (20%) follicular TC, and 5/13 (38.5%) poorly differentiated TC.
|
26354077 |
2015 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to explore TERT promoter mutations in various thyroid tumors and examine their relationship with BRAF V600E mutation, iodine intake, and clinicopathological behaviors of thyroid cancer.
|
24617711 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, testing of TERT promoter mutations on FNAB will enhance and improve the current molecular-based approaches to the management of thyroid nodules and thyroid cancer.
|
25121551 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In thyroid cancers, the presence of TERT promoter mutations (when occurring together with BRAF mutations) is significantly associated with higher TERT mRNA expression, and in glioblastoma we find a trend for increased telomerase expression in cases harbouring TERT promoter mutations.
|
23887589 |
2013 |
|
LOC110806263
|
0.100 |
Biomarker
|
disease |
BEFREE |
TERT promoter was PCR-amplified and sequenced in 42 thyroid cancer cell lines and 183 tumors: 80 papillary thyroid cancers (PTCs), 58 poorly differentiated thyroid cancers (PDTCs), 20 anaplastic thyroid cancers (ATCs), and 25 Hurthle cell cancers (HCCs).
|
23833040 |
2013 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We thus for the first time, to our knowledge, demonstrate TERT promoter mutations in thyroid cancers, that are particularly prevalent in the aggressive thyroid cancers TCPTC, PDTC, ATC and BRAF mutation-positive PTC, revealing a novel genetic background for thyroid cancers.
|
23766237 |
2013 |